Developer docs
API playgroundTry for free, no card

Search company profiles

Great Point Partners

Full company profile

uuid00005id

Namestring
Great Point Partners
Legal namestring
Great Point Partners, LLC
Websiteurl
gppfunds.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Great Point Partners is a healthcare-focused private investment firm founded in 2003 and headquartered at 165 Mason Street, Greenwich, CT, with a transatlantic office at 14 Curzon Street, London. The firm runs two complementary strategies: (i) a series of lower middle market private equity growth buyout funds (GPP I through GPP IV) that invest in profitable healthcare companies generally with $1-$10M EBITDA in the United States, Canada, and Western Europe, and (ii) the BioMedical Value Fund (BMVF), a public life sciences equity strategy employing MDs, PhDs, and PharmDs to invest in small and mid-cap publicly traded biotechnology and life sciences companies. Across both strategies, the firm manages $1.7B in private and public equity AUM and reports 30+ industry professionals.

The investment program is organized around four healthcare verticals: biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care (home care, physical therapy, urgent care), and IT-enabled healthcare businesses. Recent control acquisitions include Lyocontract (German aseptic fill/lyophilization CDMO), Eutecma (German sustainable pharma cold chain packaging), and Lenis Group (Slovenian specialty pharma distribution in Central/Eastern Europe). Portfolio activity is supported by 100+ tuck-in acquisitions across the firm's history and a dedicated eight-person sourcing team that maintains proprietary relationships, with a CEO Advisory Board and Medical Advisory Board providing operating-level guidance.

The firm earns revenue primarily through management fees on committed and invested fund capital across GPP I-IV and the BMVF, plus carried interest from successful realizations. Track record disclosed includes 37 platform acquisitions across GPP I-IV, 100+ tuck-ins averaging four per exited portfolio company, over 4x gross multiple on realized and partially realized investments as of March 2022, and 225+ directly negotiated investments through BMVF. Great Point Partners distributes via direct institutional outreach and relationship-based deal sourcing rather than intermediary channels, targeting founders and management teams of healthcare companies seeking growth capital, tuck-in acquisition support, and transatlantic expansion capability.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGreenwich, United States
HQ citystring
Greenwich
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, growth buyout funds, biopharmaceutical investments, life sciences equity, healthcare venture capital
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Funds, Trusts, and Other Financial Vehicles525
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Healthcare Private Equity Investment Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Private Equity Fund Management
TypeSubscription Recurring
Description

Management fees from private equity funds (GPP I through GPP IV) plus carried interest from successful investments. Provides growth equity, growth recapitalization, and management buyout financing to healthcare companies.

gppfunds.com
2BioMedical Value Fund (BMVF)
TypeSubscription Recurring
Description

Public life sciences equity strategy investing in small and mid-capitalization publicly traded biotechnology and life sciences companies. Deep value, fundamentally focused approach with proprietary research team.

gppfunds.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1BioMedical Value Fund (BMVF)
Description

Public life sciences equity strategy investing in small and mid-capitalization biotechnology and life sciences companies with fundamental-focused deep value investment approach.

gppfunds.com
+2 more records
Core offering1 text field

Great Point Partners is a healthcare-focused private investment firm that raises and manages lower middle market growth buyout private equity funds (GPP I through GPP IV) that acquire minority or majority stakes in growing, profitable healthcare companies in the US, Canada, and Western Europe. The firm also manages the BioMedical Value Fund (BMVF), a public equity strategy investing in small and mid-capitalization biotechnology and life sciences companies. Holdings span biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care, and healthcare IT-enabled businesses.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 4x gross multiple on realized and partially realized investments as of March 31, 2022
+4 more records
Product overview1 text field

Great Point Partners is a healthcare-focused private investment firm that operates two complementary strategies: private equity growth buyout funds (GPP I-IV) investing in private healthcare companies, and the BioMedical Value Fund (BMVF) investing in publicly traded life sciences companies. The private equity funds target growing, profitable healthcare companies with management teams focused on accelerated growth, investing across biopharmaceutical services, medical device contract manufacturing, alternate site care, and IT-enabled healthcare businesses. The BMVF employs MDs, PhDs and PharmDs to identify asymmetric risk-reward opportunities in publicly traded biotech and life sciences companies.

Product and service2 records
1Private Equity Funds (GPP I, II, III, IV)
CategoryPrivate Equity Healthcare Funds
Description

Lower middle market growth buyout private equity funds that make minority and majority investments in growing, profitable healthcare companies in the US, Canada, and Western Europe, targeting $1-10M EBITDA companies across biopharmaceutical services, alternate site care, medical device contract manufacturing, and healthcare IT-enabled businesses. Available to institutional limited partners (endowments, foundations, family offices, banks, pension funds).

2BioMedical Value Fund (BMVF)
CategoryPublic Life Sciences Equity Fund
Description

A public equity fund that invests in small and mid-capitalization, publicly traded biotechnology and life sciences companies, employing a deep value, fundamentally-focused investment approach. The investment team includes MDs, PhDs, and PharmDs who leverage proprietary research to identify asymmetric risk-reward opportunities within publicly traded life sciences companies. Available to institutional and accredited investors.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Great Point Partners acquired majority stake in Lenis Group, a Slovenian-based specialty pharmaceutical commercialization and distribution partner serving Central and Eastern Europe. As part of the investment, Michel Vounatsos (former CEO of Biogen) was appointed Board Chairman. Gilead Sciences simultaneously extended its relationship with Lenis as exclusive full-service distributor across Adriatic region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Great Point Partners acquired majority stake in Eutecma, a German developer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical cold chain shipments. The partnership supports Eutecma's global expansion and includes acquisition of proprietary reuse machine technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

MLM Medical Labs, a GPP portfolio company, acquired Cytespace Africa Laboratories to expand global presence into South Africa and Sub-Saharan Africa. Cytespace is ISO 15189 and CAP-accredited with expertise in infectious diseases including TB, malaria, and HIV.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-31
Description

American Medical Staffing, a GPP portfolio company, acquired Nexus Therapy to expand school professional talent solutions. GPP supports growth through strategic acquisitions and operational expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-13
Description

Family Resource Home Care, a Great Point Partners portfolio company, acquired Beneficial In-Home Care, Inc., a major home care agency in Eastern Washington. GPP supports portfolio companies through strategic guidance and acquisition sourcing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-22
Description

JPA Health, a GPP portfolio company, acquired akt health to expand global presence in European healthcare communications. JPA Health operates from offices across US, UK, and Switzerland providing integrated medical affairs, clinical development, and marketing services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

Great Point Partners acquired Lyocontract GmbH, a German CDMO specializing in aseptic liquid filling and lyophilization. The acquisition helps Lyocontract expand manufacturing capabilities and global distribution during increasing demand for lyophilization services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

JPA Health, a GPP portfolio company, acquired BioCentric Inc., an award-winning medical communications agency supporting pharmaceutical companies with scientific platforms, clinical trial acceleration, and HCP engagement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-02
Description

Ephicacy, a GPP portfolio company and biometrics CRO, acquired Advance Research Associates to enhance biostatistics and data management capabilities. ARA has supported over 700 clinical trials since 1996.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-19
Description

JPA Health, a GPP portfolio company, acquired True North Solutions to add commercial, clinical, and medical affairs capabilities with expertise in digital acceleration, predictive analytics, AI, and natural language processing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-09
Description

Family Resource Home Care, a GPP portfolio company, acquired Companion Care Inc. to expand access to home care in the Puget Sound region. Combined operations employ over 1,700 home care professionals.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large healthcare-focused growth equity and buyout investor with significant AUM and a broader, multi-sector mandate. Overlaps with GPP on healthcare services and pharma services platforms but operates at a larger check size.

TypeDirect peer
Description

Healthcare-specialist private equity firm focused on growth equity, recapitalizations, and buyouts in pharma services, medical devices, and healthcare services. Comparable target deal profile and sector depth to GPP.

TypeDirect peer
Description

Healthcare-dedicated PE firm with growth and buyout strategies targeting profitable lower middle market healthcare companies. Direct competitor for the same $1–10M EBITDA healthcare platform deals GPP pursues.

TypeDirect peer
Description

Lower middle market growth-oriented PE firm with a dedicated healthcare practice covering services, products, and technology. Comparable in fund size, target EBITDA range, and buy-and-build playbook.

TypeDirect peer
Description

Growth equity investor focused exclusively on healthcare services and healthcare IT companies. Directly comparable to GPP's healthcare IT-enabled businesses and alternate site care verticals.

TypeBroad incumbent
Description

Growth-oriented PE firm with a strong healthcare services franchise alongside broader B2B investments. Operates at the upper end of GPP's size band and frequently competes for healthcare services platforms.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm investing in growth equity, recapitalizations, and buyouts across healthcare services, pharma services, and medical products. Closely comparable to GPP in target company profile, fund size, and sector concentration.

TypeDirect peer
Description

Healthcare-services-heavy PE firm with a long-running franchise in lower middle market healthcare buyouts and growth equity. Highly comparable on sector specialization, fund construction, and platform-build strategy.

TypeBroad incumbent
Description

Established middle-market PE firm with a meaningful healthcare portfolio (e.g., acquirer of GPP's Vālenz exit). Competes in similar deal sizes and stages, providing benchmark valuation reference points.

TypeDirect peer
Description

Healthcare-focused PE firm making control and growth investments in lower middle market healthcare services, products, and technology companies. Direct competitor for the same profitable, sub-$10M EBITDA platforms GPP targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment73 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Great Point Partners

Healthcare Private Equity Investment Managementgppfunds.com

What Great Point Partners does

Great Point Partners is a healthcare-focused private investment firm founded in 2003 and headquartered at 165 Mason Street, Greenwich, CT, with a transatlantic office at 14 Curzon Street, London. The firm runs two complementary strategies: (i) a series of lower middle market private equity growth buyout funds (GPP I through GPP IV) that invest in profitable healthcare companies generally with $1-$10M EBITDA in the United States, Canada, and Western Europe, and (ii) the BioMedical Value Fund (BMVF), a public life sciences equity strategy employing MDs, PhDs, and PharmDs to invest in small and mid-cap publicly traded biotechnology and life sciences companies. Across both strategies, the firm manages $1.7B in private and public equity AUM and reports 30+ industry professionals.

The investment program is organized around four healthcare verticals: biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care (home care, physical therapy, urgent care), and IT-enabled healthcare businesses. Recent control acquisitions include Lyocontract (German aseptic fill/lyophilization CDMO), Eutecma (German sustainable pharma cold chain packaging), and Lenis Group (Slovenian specialty pharma distribution in Central/Eastern Europe). Portfolio activity is supported by 100+ tuck-in acquisitions across the firm's history and a dedicated eight-person sourcing team that maintains proprietary relationships, with a CEO Advisory Board and Medical Advisory Board providing operating-level guidance.

The firm earns revenue primarily through management fees on committed and invested fund capital across GPP I-IV and the BMVF, plus carried interest from successful realizations. Track record disclosed includes 37 platform acquisitions across GPP I-IV, 100+ tuck-ins averaging four per exited portfolio company, over 4x gross multiple on realized and partially realized investments as of March 2022, and 225+ directly negotiated investments through BMVF. Great Point Partners distributes via direct institutional outreach and relationship-based deal sourcing rather than intermediary channels, targeting founders and management teams of healthcare companies seeking growth capital, tuck-in acquisition support, and transatlantic expansion capability.

Great Point Partners firmographics

Firmographics
Name
Great Point Partners
Legal name
Great Point Partners, LLC
Website
https://gppfunds.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Great Point Partners industry classification

Industry
Product category
Healthcare Private Equity Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Healthcare private equity
  • Growth buyout funds
  • Biopharmaceutical investments
  • Life sciences equity
  • Healthcare venture capital

Where Great Point Partners is headquartered

Location

Headquarters

HQ city
Greenwich
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Great Point Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Private Equity Fund Management: Management fees from private equity funds (GPP I through GPP IV) plus carried interest from successful investments. Provides growth equity, growth recapitalization, and management buyout financing to healthcare companies.
  2. BioMedical Value Fund (BMVF): Public life sciences equity strategy investing in small and mid-capitalization publicly traded biotechnology and life sciences companies. Deep value, fundamentally focused approach with proprietary research team.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Great Point Partners product offering

Product offering

Core offering

Great Point Partners is a healthcare-focused private investment firm that raises and manages lower middle market growth buyout private equity funds (GPP I through GPP IV) that acquire minority or majority stakes in growing, profitable healthcare companies in the US, Canada, and Western Europe. The firm also manages the BioMedical Value Fund (BMVF), a public equity strategy investing in small and mid-capitalization biotechnology and life sciences companies. Holdings span biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care, and healthcare IT-enabled businesses.

Product overview

Great Point Partners is a healthcare-focused private investment firm that operates two complementary strategies: private equity growth buyout funds (GPP I-IV) investing in private healthcare companies, and the BioMedical Value Fund (BMVF) investing in publicly traded life sciences companies. The private equity funds target growing, profitable healthcare companies with management teams focused on accelerated growth, investing across biopharmaceutical services, medical device contract manufacturing, alternate site care, and IT-enabled healthcare businesses. The BMVF employs MDs, PhDs and PharmDs to identify asymmetric risk-reward opportunities in publicly traded biotech and life sciences companies.

Differentiator

Problem solved

Functional benefit

Brands

  • BioMedical Value Fund (BMVF): Public life sciences equity strategy investing in small and mid-capitalization biotechnology and life sciences companies with fundamental-focused deep value investment approach.
  • Great Point Partners IV (GPP IV)
  • Great Point Partners III (GPP III)

Products and services

  • Private Equity Funds (GPP I, II, III, IV) Lower middle market growth buyout private equity funds that make minority and majority investments in growing, profitable healthcare companies in the US, Canada, and Western Europe, targeting $1-10M EBITDA companies across biopharmaceutical services, alternate site care, medical device contract manufacturing, and healthcare IT-enabled businesses. Available to institutional limited partners (endowments, foundations, family offices, banks, pension funds).
  • BioMedical Value Fund (BMVF) A public equity fund that invests in small and mid-capitalization, publicly traded biotechnology and life sciences companies, employing a deep value, fundamentally-focused investment approach. The investment team includes MDs, PhDs, and PharmDs who leverage proprietary research to identify asymmetric risk-reward opportunities within publicly traded life sciences companies. Available to institutional and accredited investors.

Quantifiable outcome

  • Over 4x gross multiple on realized and partially realized investments as of March 31, 2022
  • +4 more outcomes

Companies that use Great Point Partners

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles2 records

Great Point Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Great Point Partners partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core.

  • Lenis GroupcoreStrategic or Co-development Partner · 16 December 2025Great Point Partners acquired majority stake in Lenis Group, a Slovenian-based specialty pharmaceutical commercialization and distribution partner serving Central and Eastern Europe. As part of the investment, Michel Vounatsos (former CEO of Biogen) was appointed Board Chairman. Gilead Sciences simultaneously extended its relationship with Lenis as exclusive full-service distributor across Adriatic region.
  • EutecmacoreStrategic or Co-development Partner · 11 June 2025Great Point Partners acquired majority stake in Eutecma, a German developer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical cold chain shipments. The partnership supports Eutecma's global expansion and includes acquisition of proprietary reuse machine technology.
  • MLM Medical LabscoreStrategic or Co-development Partner · 3 June 2025MLM Medical Labs, a GPP portfolio company, acquired Cytespace Africa Laboratories to expand global presence into South Africa and Sub-Saharan Africa. Cytespace is ISO 15189 and CAP-accredited with expertise in infectious diseases including TB, malaria, and HIV.
  • American Medical StaffingcoreStrategic or Co-development Partner · 31 March 2025American Medical Staffing, a GPP portfolio company, acquired Nexus Therapy to expand school professional talent solutions. GPP supports growth through strategic acquisitions and operational expertise.
  • Family Resource Home CarecoreStrategic or Co-development Partner · 13 February 2025Family Resource Home Care, a Great Point Partners portfolio company, acquired Beneficial In-Home Care, Inc., a major home care agency in Eastern Washington. GPP supports portfolio companies through strategic guidance and acquisition sourcing.
  • JPA HealthcoreStrategic or Co-development Partner · 22 July 2024JPA Health, a GPP portfolio company, acquired akt health to expand global presence in European healthcare communications. JPA Health operates from offices across US, UK, and Switzerland providing integrated medical affairs, clinical development, and marketing services.
  • Lyocontract GmbHcoreStrategic or Co-development Partner · 13 June 2024Great Point Partners acquired Lyocontract GmbH, a German CDMO specializing in aseptic liquid filling and lyophilization. The acquisition helps Lyocontract expand manufacturing capabilities and global distribution during increasing demand for lyophilization services.
  • JPA HealthcoreStrategic or Co-development Partner · 23 May 2024JPA Health, a GPP portfolio company, acquired BioCentric Inc., an award-winning medical communications agency supporting pharmaceutical companies with scientific platforms, clinical trial acceleration, and HCP engagement.
  • Ephicacy Consulting GroupcoreStrategic or Co-development Partner · 2 May 2024Ephicacy, a GPP portfolio company and biometrics CRO, acquired Advance Research Associates to enhance biostatistics and data management capabilities. ARA has supported over 700 clinical trials since 1996.
  • JPA HealthcoreStrategic or Co-development Partner · 19 October 2023JPA Health, a GPP portfolio company, acquired True North Solutions to add commercial, clinical, and medical affairs capabilities with expertise in digital acceleration, predictive analytics, AI, and natural language processing.
  • Family Resource Home CarecoreStrategic or Co-development Partner · 9 August 2023Family Resource Home Care, a GPP portfolio company, acquired Companion Care Inc. to expand access to home care in the Puget Sound region. Combined operations employ over 1,700 home care professionals.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Great Point Partners competitors and assessment

Company assessment

Broad incumbents

  • New Mountain Capital: Large healthcare-focused growth equity and buyout investor with significant AUM and a broader, multi-sector mandate. Overlaps with GPP on healthcare services and pharma services platforms but operates at a larger check size.
  • Parthenon Capital Partners: Growth-oriented PE firm with a strong healthcare services franchise alongside broader B2B investments. Operates at the upper end of GPP's size band and frequently competes for healthcare services platforms.
  • Kelso & Company: Established middle-market PE firm with a meaningful healthcare portfolio (e.g., acquirer of GPP's Vālenz exit). Competes in similar deal sizes and stages, providing benchmark valuation reference points.

Direct peers

  • Avista Capital Partners: Healthcare-specialist private equity firm focused on growth equity, recapitalizations, and buyouts in pharma services, medical devices, and healthcare services. Comparable target deal profile and sector depth to GPP.
  • Frazier Healthcare Partners: Healthcare-dedicated PE firm with growth and buyout strategies targeting profitable lower middle market healthcare companies. Direct competitor for the same $1–10M EBITDA healthcare platform deals GPP pursues.
  • Excellere Partners: Lower middle market growth-oriented PE firm with a dedicated healthcare practice covering services, products, and technology. Comparable in fund size, target EBITDA range, and buy-and-build playbook.
  • Health Enterprise Partners (HEP): Growth equity investor focused exclusively on healthcare services and healthcare IT companies. Directly comparable to GPP's healthcare IT-enabled businesses and alternate site care verticals.
  • Linden Capital Partners: Healthcare-focused middle-market private equity firm investing in growth equity, recapitalizations, and buyouts across healthcare services, pharma services, and medical products. Closely comparable to GPP in target company profile, fund size, and sector concentration.
  • Welsh, Carson, Anderson & Stowe (WCAS): Healthcare-services-heavy PE firm with a long-running franchise in lower middle market healthcare buyouts and growth equity. Highly comparable on sector specialization, fund construction, and platform-build strategy.
  • WindRose Health Investors: Healthcare-focused PE firm making control and growth investments in lower middle market healthcare services, products, and technology companies. Direct competitor for the same profitable, sub-$10M EBITDA platforms GPP targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Great Point Partners social profiles

Digital presence

Great Point Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Great Point Partners leadership team

Management profile

Number of profiles

Profiles12 records

Great Point Partners subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Great Point Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Great Point Partners M&A and investment

M&A and investment

M&A6 records

Investments73 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Great Point Partners

What does Great Point Partners do?

Great Point Partners is a healthcare-focused private investment firm that raises and manages lower middle market growth buyout private equity funds (GPP I through GPP IV) that acquire minority or majority stakes in growing, profitable healthcare companies in the US, Canada, and Western Europe. The firm also manages the BioMedical Value Fund (BMVF), a public equity strategy investing in small and mid-capitalization biotechnology and life sciences companies. Holdings span biopharmaceutical services and supplies, medical device contract manufacturing, alternate site care, and healthcare IT-enabled businesses.

Is Great Point Partners a public or private company?

Great Point Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Great Point Partners founded?

Great Point Partners was founded in 2003. It employs 11 to 50 people.

Where is Great Point Partners based?

Great Point Partners is headquartered in Greenwich, United States, in the North America region.

How does Great Point Partners make money?

Two revenue lines are on record. Private Equity Fund Management is the primary driver. The others are bioMedical Value Fund (BMVF).

Who are Great Point Partners's main competitors?

Broad incumbents on record are New Mountain Capital, Parthenon Capital Partners and Kelso & Company. Direct peers are Avista Capital Partners, Frazier Healthcare Partners, Excellere Partners, Health Enterprise Partners (HEP), Linden Capital Partners, Welsh, Carson, Anderson & Stowe (WCAS) and WindRose Health Investors.

Does Great Point Partners have an API?

No public API is recorded for Great Point Partners.

What industry is Great Point Partners in?

Great Point Partners's product category is Healthcare Private Equity Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogGreat Point Partners Named to Inc.’s 2026 List of Founder-Friendly Investors for Fourth Consecutive YearGreat Point Partners was named to Inc.'s 2026 Founder-Friendly Investors list for the fourth consecutive year. The firm, founded in 2003, has partnered with over 100 health care companies and manages about $1.7 billion in capital.InvestorsinhealthcareGermany: Labcorp acquires MLM Medical Labs from Great Point PartnersLabcorp acquired Germany-based MLM Medical Labs from Great Point Partners, with financial terms undisclosed. The deal expands Labcorp's laboratory footprint and makes it the only central lab provider with wholly owned labs across four continents. MLM had quadrupled its revenue and EBITDA under GPP ownership.BioSpaceGreat Point Partners III Sells MLM Medical Labs to LabcorpGreat Point Partners sold its portfolio company MLM Medical Labs to Labcorp. Under GPP's ownership, MLM quadrupled revenue and EBITDA, expanded from Germany to the US and South Africa, and completed two acquisitions. The deal was advised by William Blair & Company.Pulse 2.0VetnCare Acquires Holistic Veterinary Care In Sixth Add-On Under Great Point PartnersVetnCare, a Northern California veterinary hospital group backed by healthcare private equity firm Great Point Partners, has acquired Holistic Veterinary Care, an Oakland-based integrative veterinary practice. The deal marks VetnCare's sixth acquisition since Great Point Partners invested and the first completed under CEO Matt Kirchner, with founder Dr. Gary Richter transitioning to Clinical Director. The acquisition extends VetnCare's model into integrative and alternative medicine as part of its strategy to deepen care options within its existing geographic footprint.BioSpaceSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesSagimet Biosciences reported Q1 2026 financial results and corporate updates, including a $175M equity financing and a planned Phase 3 trial of denifanstat in moderate to severe acne. The company expects its cash and financing to fund operations through 2028, including the trial's data readout.GlobeNewswireInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesInflaRx completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million in gross proceeds. The company will use the net proceeds for pipeline activities and working capital. The offering included participation from new and existing investors, with Guggenheim Securities as lead bookrunner.BioSpaceInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesInflaRx priced a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share, with the offering expected to close on May 7, 2026. The company will use net proceeds for pipeline activities and working capital. The offering includes participation from new and existing investors.GlobeNewswireInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesInflaRx priced a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share, with the offering expected to close on May 7, 2026. The company will use net proceeds for pipeline activities and working capital. The offering includes participation from new and existing investors.GlobeNewswireBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com released its 2026 Biopharmaceutical CMO and CRO Market Report, showing the market growing from $35.6 billion in 2025 to $38.01 billion in 2026 at a 6.8% CAGR, with projections reaching $48.79 billion by 2030 at a 6.4% CAGR. The growth is driven by increasing biologic drug development complexity, rising R&D costs, expanded clinical trial activities, and the surge in biosimilar development. Notable strategic transactions in the sector include Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH, both in June 2024, while North America remains the largest regional market and Asia-Pacific is forecast to be the fastest-growing region.YahooBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe biopharmaceutical Contract Manufacturing Organizations (CMO) and Contract Research Organizations (CRO) market is projected to grow from $38.01 billion in 2026 to $48.79 billion by 2030, driven by increasing R&D investments, demand for biologics, and rising clinical trial activities. Strategic partnerships and acquisitions are reshaping the competitive landscape, including Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH. Industry trends indicate continued outsourcing of biologic drug manufacturing and expansion of cell and gene therapy capabilities as key growth drivers through 2030.